The Pharmacovigilance Risk Assessment Committee (PRAC) publishes its recommendations of wording to be introduced within the product information of medicinal products, following the evaluation of pharmacovigilance signals during its meeting which has been held on 25-28 October 2021. For other signals the PRAC needs more data before to conclude.
See in the table below a summary of PRAC conclusions …
